Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Restructuring Costs (2017)

Charles River Laboratories International (CRL) posted Restructuring Costs of $18.1 million for Q4 2017.

Analysis

Charles River Laboratories International (CRL) Restructuring Costs (2017) Analysis & Trends

Charles River Laboratories International has reported Restructuring Costs for 1 years, with the latest figure at $18.1 million in Q4 2017.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn
6 Evotec SE 574.75 Mn 148.87 Mn -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn
10 VivoSim Labs 1.37 Mn 1.37 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 30, 2017 18.10 Mn